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120 character summary:   Lung function changes in newborn screened infants with Cystic 
Fibrosis are mild and transient during the first 2 years of life. 
Word count: 3716 
 
 
 
 
This article has an online data supplement.  
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ABSTRACT 
With the advent of novel designer molecules for cystic fibrosis (CF) treatment, there is huge 
need for early life clinical trial outcomes, such as infant lung function (ILF). We investigated 
the degree and tracking of ILF abnormality during the first two years of life in CF newborn 
screened infants.   
Forced Expiratory Volume (FEV0.5), lung clearance index (LCI), and plethysmographic 
functional residual capacity (FRCpleth) were measured at ~3months, 1yr and 2yrs in 62 infants 
with CF and 34 controls.  
By 2yrs there was no significant difference in zFEV0.5 between CF and controls, whereas 
mean LCI z-score (zLCI) was 0.81(95% CI: 0.45;1.17) higher in CF. However, there was no 
significant association between zLCI at 2yrs with either 3month or 1yr results. Despite 
minimal average group changes in any ILF outcome during the second year of life, marked 
within-subject changes occurred. No child had abnormal LCI or FEV0.5 on all test occasions, 
precluding the ability to identify ‘high-risk’ infants in early life. 
In conclusion, changes in lung function are mild and transient during the 1
st
 2yrs of life in 
newborn screened infants with CF when managed according to a standardised UK treatment 
protocol. Their potential role in tracking disease to later childhood will be ascertained by 
ongoing follow up. 
 
Abstract word count: 206 
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Key words: Cystic fibrosis, newborn screening, infant lung function testing, lung clearance 
index, plethysmography, raised volume technique.  
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INTRODUCTION 
The advent of gene mutation class specific therapies for cystic fibrosis (CF) and 
demonstration of their efficacy in older children and adults has led to demands to introduce 
them in infancy, before significant lung damage occurs. However, if such trials are to be 
undertaken, highly sensitive trial end-points are needed to monitor both for efficacy and 
safety during this vulnerable period of rapid lung growth.  A recent European Cystic Fibrosis 
Society Clinical Trial Network consensus concluded that infant lung function (ILF) testing 
using the raised volume rapid thoracic compression (RVRTC) technique should not be used 
as a primary outcome in clinical trials of infants with CF until further evidence is available[1]. 
Similar recommendations have been made with respect to infant multiple breath washout 
(MBW)[2].  
The London Cystic Fibrosis Collaboration (LCFC; (htttp://www.ucl.ac.uk/london-cystic-
fibrosis)) is following up a newborn screened (NBS) CF cohort and contemporaneous 
controls. We have previously reported that at 3 months, Forced Expired Volume in 0.5 
seconds (FEV0.5) was reduced in 25%(17/68) of infants while Lung Clearance Index (LCI) was 
elevated in 21%(15/70)[3]. ILF at 1yr was predicted by that at 3mth and impressively FEV0.5 
improved over the first year of life with standard UK treatment[4]. We suggested that those 
infants with abnormal ILF (e.g. an elevated LCI) in early life may be a sub-group in whom 
specific treatment interventions would make the greatest difference. Yet if innovative 
therapies with the potential to modify disease are to be deployed, there must be both 
clinical need and the ability to assess outcome. If our observed improvement in ILF was 
sustained between 1-2yrs with standard treatment alone in NBS infants, this would have 
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significant implications for clinical trial design involving novel treatments for CF in early life 
when the developing lung is potentially at its most vulnerable[5].  
The aim of this observational study was to investigate the tracking of ILF in the first 2 years 
of life in CF NBS infants managed with standard UK therapy, and consider the implications of 
this in relation to use of such outcomes as endpoints in clinical trials conducted over this 
time period. Based on our previous findings at 1yr, we hypothesised that group stability of 
ILF would be maintained to 2yrs in NBS CF infants.  Some results presented here have been 
published as abstracts[6-8].  
MATERIAL AND METHODS 
Full details of both the recruitment of the LCFC cohort of infants with CF diagnosed by NBS 
and contemporaneous healthy controls, and the prospective observational study design 
have been published[3, 4].  In brief, NBS CF infants born between January 2009 and July 
2011 who were referred to the six specialist CF centres in the London CF Collaboration 
(LCFC) were eligible for recruitment. Healthy controls were recruited contemporaneously 
from Homerton University Hospital, East London. Infants were ineligible if born<36 weeks 
gestation or had coexisting congenital abnormalities. The study was approved by the North 
Thames Multi-Centre Research Ethics Committee (#09/HO71/314). Informed written 
parental consent was obtained. Participating centres prospectively completed Case Record 
Forms (CRF) at diagnosis and at each subsequent clinic visit. CF infants were started on 
multivitamins and vitamin E, pancreatic enzyme replacement therapy where appropriate 
and, in accord with UK CF Trust guidelines, oral prophylactic flucloxacillin, according to a 
standardised treatment protocol[4].  All subjects in the LCFC NBS CF cohort attending 
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between 1.5- 2.4yrs with a previous visit at 3mths and/or 1yr were included in this 2yr 
follow-up. Subjects were free from acute respiratory tract infection for at least 3 weeks 
prior to testing. MBW, plethysmography and RVRTC were performed on each test occasion 
at the ILF laboratory at UCL Great Ormond St Institute of Child Health as described 
previously[3, 4]. The main ILF outcomes were LCI, plethysmographic functional residual 
capacity (FRCpleth) and FEV0.5. Oral sedation with chloral hydrate (60-100mg/kg; maximum 
1000mg) was administered prior to each occasion. MBW results were analysed using 
custom-made software (P.Gustafsson, version 2012). ILF data were electronically exported 
to a research database (Re-Base software, Re-Base, UK) where data for each child were 
linked according to test occasion with demographic and clinical information. ILF outcomes 
were converted to z-scores using published reference equations derived from healthy 
infants and young children using identical equipment and protocols[9-11]. Clinical 
information was collected at routine clinical visits and at each test occasion, including 
history of intravenous antibiotics and airway microbiology results (from cough swabs or 
from bronchoalveolar lavage at 1yr).  
Statistical analysis  
Differences between control and CF groups at each test occasion were compared using 
unpaired t-tests. We planned to study at least 60 NBS CF children and 30 healthy controls at 
~2yrs of age to provide 80% power to detect differences of at least 0.725 z-scores in the 
three primary ILF outcomes (90% power to detect differences of 0.825 z-scores) at the 5% 
significance level.  
Individual line plots over time were used to illustrate change within-subject between-tests. 
Paired t-tests were used to quantify average change between any two test occasions within 
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groups and the SD to quantify variability of those changes. Unpaired t-tests were used to 
compare change over time between groups. To further investigate tracking of ILF in children 
with CF, abnormalities on each test occasion were defined as >1.96z-scores for LCI and 
FRCpleth or <−1.96z-scores for FEV0.5.  
Regression was used to investigate any relationship between change in ILF and interval 
between tests. To investigate change over time according to disease status and treatment 
severity, CF subjects were grouped according to whether they had received intravenous 
antibiotics or isolated relevant pathogens (Pseudomonas aeruginosa (PsA), Staphylococcus 
aureus (SA) or Haemophilus influenzae (HI)) in respiratory culture by the time of their 2yr 
test. Sample estimates (differences between groups, changes over time) are presented with 
95% confidence intervals (CI) to facilitate interpretation.  
 
RESULTS 
62 NBS CF infants and 34 healthy controls with prior ILF results had tests repeated at ~2yrs 
of age. The study population is summarised in Table E1 (online supplement, OLS). The 
proportion of subjects with technically satisfactory ILF results at each test occasion ranged 
from 77-98% (Table E2,OLS). Results presented here focus on the relationship between ILF 
results at 1 and 2yrs, as tracking between 3mths to 1yr has been published[4].  
Cross sectional data 
Cross-sectional results for both CF and healthy infants at 2yrs are summarised in Table 1, 
with results at 3mths and 1yr in Table E3(OLS). At 1yr, there were significant differences 
between CF and control groups for all three primary LF outcomes (Table E3b). However by 
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2yrs, there was no significant difference in FEV0.5 between CF and controls. Over the same 
time period, differences between CF and controls increased slightly by 0.12 z-scores for LCI,  
with  a mean (95% CI) difference of 0.81(0.45;1.17) z-scores between groups by 2yrs, (Fig 1 
and Table 1) whereas difference in zFRCpleth remained stable. The impact of using recently 
updated published RVRTC reference equations is summarised in the OLS. 
Change over time 
There was no significant group change over time for any ILF outcome in controls. By 
contrast, as reported previously[4], there was a significant improvement in FEV0.5 in CF 
infants, particularly in the first year of life (Table E4).  A comparison of changes in lung 
function during the second year of life between CF and controls is summarised in Table 2. 
While mean changes in ILF were minimal during the second year of life, the relatively wide 
SDs reflect marked within-subject change between test occasions.  
 ‘Abnormal’ lung function 
The proportion of CF infants with ‘normal’ or ‘abnormal’ results for each ILF outcome at 
each test occasion is shown in Table 3. At the time of the 2yr test, abnormal results were 
only detected in 15%(9/61) of CF infants for LCI, 19%(11/57) for FRCpleth and 7%(4/56) for 
FEV0.5. No child had abnormalities in all three outcomes on any test occasion. No child had 
an abnormal LCI or FEV0.5 on all test occasions, and only 2/44(5%) CF infants had an 
abnormal FRCpleth on all test occasions. 
The association of results between different test occasions within each of the primary ILF 
outcomes is shown in Fig E1. In contrast to the highly significant relationship in both FRCpleth 
and FEV0.5 across all test occasions in infants with CF, LCI at 2yr was not predicted by that 
measured at either 3mth or 1yr. Of the 10 CF infants with an abnormal LCI at 1yr, all but two 
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had a result within the normal range by ~2yr (Fig E1). Similarly, only 2/9 infants with 
abnormal LCI at 2yr also had an abnormal 1yr result.   
Clinical status 
Line plots demonstrating change over time of zLCI at the individual level are shown in Fig 2, 
with CF infants separated according to PsA status. Similar plots for other ILF outcomes are 
shown in Figure E2(OLS), along with a comparison of results according to whether infants 
had ever received IV antibiotics. Considerable within-subject change in LCI occurred 
between tests even in health and the magnitude of such change was not related to either 
the isolation of PsA or treatment with IV antibiotics by the final ILF test in those with CF (Fig 
2, Fig E2 and Table E6(OLS)). The lack of relationship between the magnitude or direction of 
change in LCI with respect to PsA status or treatment with IV antibiotics is also illustrated in 
Figure E3(OLS). A similar pattern was observed for FRCpleth and FEV0.5, with the exception of 
the greater improvement in FEV0.5 during the 1
st
 year of life in infants who did not isolate 
PsA by their final ILF test (Table E6(OLS)). Similarly, the magnitude or direction of change 
between tests was not related to whether or not infants had isolated either SA or HI, or any 
major CF Pathogen (PsA, SA or HI) by 2yr (data not shown). Results of regression analysis 
revealed no significant association between magnitude of within-subject, between-test 
change in ILF and interval between tests.  
 
DISCUSSION 
Summary of main findings 
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We report for the first time that in a NBS CF cohort treated with UK standardised therapy, 
there was no significant difference in FEV0.5 between healthy controls and CF infants by 2yrs 
of age. In contrast to reports by the Australian Respiratory Early Surveillance Team for CF 
(AREST–CF)[12], NBS CF babies in our cohort did not experience deteriorating lung function 
over the first 2yrs of life. While mean zLCI and zFRCpleth were significantly higher in CF 
infants than controls at 2yrs, neither increased significantly during the second year of life.  
Those individuals who did exhibit abnormal ILF at any one point often reverted to normality 
on subsequent testing, suggesting that during infancy such changes are reversible rather 
than progressive. Within our NBS CF cohort we could not identify any individual with 
consistently abnormal LCI or FEV0.5 who could thus be preferentially selected to receive 
novel therapies. In contrast to the relationship between 3mth and 1yr results previously 
reported in this cohort [4], there was no significant association between zLCI at 2yrs and 
that at either 3mth or 1yr.  
Strengths and limitations 
The strengths of this study include prospective recruitment of the LCFC NBS cohort and 
contemporaneous controls, allowing unique insights into the impact of CF on early life 
pulmonary function. Without controls, an understanding of change over time would be 
challenging. Results were interpreted using z-scores from recently published reference 
equations, derived using identical equipment and methodology[9-11]. Inclusion of a control 
group, who were similar in terms of body size, also ensured that any changes in the 
physiological dead space to tidal volume ratio over the study period would not influence 
interpretation of LCI results. The equipment and techniques for measuring ILF remained 
standardised and constant throughout the study period, as did the sedation protocol.  
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Technical success rates for ILF tests in our NBS LCFC cohort continue to be better than other 
longitudinal studies involving infants with CF (as recently summarised by the European CF 
Society Clinical Trial Network)[1], particularly when compared with those which involved 
testing across multiple centres[13]. 
A range of ILFTs were performed to reflect the various aspects of pathophysiology most 
commonly reported in CF lung disease, with the primary outcomes of LCI, FRCpleth and FEV0.5  
selected a priori to avoid any risk of data dredging or misinterpretation due to use of an 
excessive number of measurements. We have not reported the tidal breathing ratio, having 
previously determined that it is not useful in identifying diminished airway function in 
infants with CF, nor respiratory rate, which is poorly predictive of diminished airway 
function in this population[14]. While rarely reported, between-test variability within our 
control group is in keeping with that in older children, variability of up to 1.2z scores in FEV1 
being recorded in 5-11 year olds over the course of a year[15]. Using an observational study 
design, Davis et al did not recommend inclusion of FEV0.5 or FRCpleth measured during infancy 
as a primary efficacy endpoint in clinical trials due to within-subject variability between 
tests, technical challenges and the requirement for large sample sizes to detect efficacy [13].   
Judgements regarding the clinical usefulness of any biomarker requires an assessment of its 
reliability, validity and responsiveness, as summarised in a recent review [16]. However, 
objective assessments of surrogate measures such as lung function require a different 
approach, particularly when such measurements are being undertaken in infants. Sedation 
is required for most infant lung function tests, administration of which is not advised either 
in the presence of an exacerbation or at frequent intervals. Furthermore, sedation may 
cause at least temporary disruption of sleep patterns and the duration of these tests (up to 
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3-4 hours including the period to induce sleep) can place a real burden on parents if they are 
expected to attend for follow up visits more frequently than 6 monthly, a factor which 
would reduce compliance in any clinical trial. It is therefore extremely difficult to use ILFTs 
to assess acute response to either exacerbations or treatment reliably. However, by 
undertaking repeated measurements at approximately 9 monthly intervals during periods of 
clinical stability, information regarding the magnitude of any changes and extent to which 
ILF tracks during the first 2 years of life in NBS infants with CF managed on standard care can 
be obtained, knowledge of which is vital if planning to use such tests in future clinical trials. 
In addition to natural variability observed in health, improvement of LF by 2yrs following 
earlier ‘abnormalities’ in CF infants could reflect treatment intensification in the interim, 
either in response to symptomatic deterioration or following the identification of pathogens 
such as PsA.  The grouping of infants into those that had and had not isolated PsA or been 
treated with IV antibiotics was simply to reflect relative disease burden, rather than an 
attempt to relate ILF to specific clinical events or interventions. Although  our study was not 
designed to determine the dynamic effect of exacerbations or treatment response on ILF, 
neither the isolation of PsA nor treatment with intravenous antibiotics by 2yrs was 
associated with the magnitude of ILF variability over this period. The influence of early life 
exacerbations on childhood lung function may however become detectable at subsequent 
follow-up [17].  
Conclusions from a study such as this might differ in regions with differing treatment 
protocols, prevalence of CF gene mutations or modifier genes, or environmental exposures 
The antibiotic protocols used were defined primarily to standardise care between the LCFC 
centres in line with current UK practice rather than reflecting any evidence that antibiotic 
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prophylaxis would impact favourably (or otherwise) on ILF outcomes. Ideally study clinicians 
would have remained blinded to results, but this was not considered to be ethical in an 
observational study such as this. While this could be viewed as a potential weakness, given 
the complete overlap in direction and variability of change in ILF between those with and 
without prior IV antibiotics or CF pathogens such as PsA, this is unlikely to have influenced 
our findings. In our study, PsA had been isolated on at least one occasion in 32 (52%) by the 
time of the 2yr test, though only 4 infants had any evidence of chronic infection. The 
relatively high frequency of ‘PsA ever’ by 2years of age is in keeping with  recent reports and 
reflects the fact that this cohort were under close surveillance, PsA being isolated not only 
from the 1yr BAL but from regular cough swabs throughout the study period. . However, we 
also accept that diagnosis of lower respiratory infection status in infants is difficult, and 
incorrect classification remains a possibility. 
 
We performed high resolution computed tomography (HRCT) scans at one year of age, but 
the changes were so mild, and the variability between observers consequently so great[18], 
that we did not feel ethically justified in repeating the scan at 2yr unless clinically indicated 
for an individual; the continued relative normality of lung function is supportive of that 
decision.  
Clinical significance 
Our study design was a pragmatic means of informing future clinical trials in that it provides 
evidence both on the magnitude of ILF abnormalities that might be expected on standard 
therapy, as well as the extent to which such changes track during the first 2 years of life, in 
exactly the group of infants who might be recruited to an intervention study. Without 
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observational data it would be difficult to design a study to evaluate effects of any novel, 
medium-term interventions. This evidence is strengthened by our ability to interpret results 
in relation to the normal variability that occurs in health, since we not only had a 
contemporaneous control group but reference equations derived using identical methods 
and equipment. The clinical importance of ILF tests in CF lung disease will be clarified by the 
continuing follow-up of this cohort into the preschool years[19], which will establish 
whether there is evidence of tracking over a longer time period. Although mean LCI was 
static over the second year of life in our cohort, the small increase in z-scores in comparison 
to controls may represent a degree of deterioration at the group level which may become 
more apparent with subsequent follow-up. The importance of physiological outcomes 
during the preschool years is already recognised, as results can reflect subsequent status at 
school age[20], and  a recent study has confirmed that LCI is a useful marker to track early 
disease progression in preschool children with CF [21].  
Clinical efficacy of treatment interventions assessed according to functional trial endpoints 
is possible to demonstrate even when baseline results are within the normal range, as 
illustrated by results from the phase III clinical trial of the cystic fibrosis transmembrane 
regulator potentiator ivacaftor in children aged 6-11yrs with a G551D mutation[22].  
However, in contrast to older children or possibly a clinically diagnosed infant cohort, 
interventions aimed at reducing the rate of decline (rather than improvement) in FEV would 
not be appropriate in an infant NBS population such as ours, since FEV0.5 improved to 
normal levels during the first two years of life with standard UK care alone.  While attempts 
could be made to diminish the mild elevations of LCI or FRCpleth observed in CF infants by 2 
years of age, the transient nature of within-subject abnormalities at 3mth or 1yr in infants 
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treated with UK standard care alone calls into question the clinical relevance of this 
approach.  
As previously reported for our CF NBS cohort, 1yr ILF was predicted by results obtained from 
testing at 3mths[4]. However the combination of relatively normal results at 2yrs and 
marked bi-directional within-subject change over time (Fig E2 OLS), question the value of 
modelling ILF outcomes at 2yrs. We therefore analysed results at 2yrs with respect to those 
at 3mths and 1yr separately, rather than in a repeated measures analysis. Any long-term 
value of ILF in terms of predicting later CF disease status will become clearer as our current 
cohort is followed up through the preschool years and beyond. The transient nature of the 
observed changes in lung function in our cohort is encouraging, but does mean that our 
previous proposal to try to identify a ‘high-risk’ subgroup of NBS CF infants based on 
‘abnormalities’ at either 3mths or 1yr of age is not feasible.  
Comparison with other studies 
To our knowledge, the only other prospective longitudinal study reporting ILF outcomes in 
NBS infants with CF is that from the AREST-CF group. Although both AREST-CF and the LCFC 
detected deficits in ILF by around 3mths in such infants[3, 12, 23], results from these two 
studies are widely discrepant at later time points. Instead of improvement to one year and 
maintenance of ILF to 2 years as reported here, lung function appeared to deteriorate 
significantly over this period in the AREST-CF infants (mean(SD) FEV0.5 z-score being -
1.4(1.2), -2.4(1.1) and -4.3(1.6) at around 5mth, 1yr and 2yrs of age)[12]. Of note, however, 
was the conversion of RVRTC outcomes to z-scores using historical control data collected 
with different equipment[24], and the absence of a contemporaneous control group within 
the AREST-CF study. Possible explanations for the differences between results from these 
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two NBS cohorts have recently been summarised by Bush and Sly[25]. Interestingly, 
continued longitudinal follow-up of the AREST-CF cohort has reported much better lung 
function at school-age than might be expected from their infant results[26]. Although our 
results contrast with those reported by AREST-CF, Davis et al also reported normal FEV0.5 yet 
high within-subject change between ILF tests in CF infants participating in their inhaled 
hypertonic saline clinical trial[27]. Continued follow up of both the LCFC and AREST-CF 
cohorts will provide crucial insights to the natural history of CF lung disease, and allow 
evaluation of proposed predictors of abnormal lung function or structural changes on chest 
HRCT in later childhood.  
 
CONCLUSION 
We show, in contrast to previous studies from AREST-CF, that lung function as assessed by 
measurements of LCI, FRCpleth and FEV0.5 is well preserved to 2 years of age in our cohort of 
NBS infants with CF managed with UK standard care.  The transient nature of any 
abnormalities observed during this time period suggests that such changes may remain 
reversible during early life. Whether these results can be translated to other CF populations, 
such as infants not receiving prophylactic antibiotic therapy or undergoing regular 
surveillance by infant lung function, is unclear. Nevertheless, the relative normality of infant 
lung function to 2 years of age in this prospectively followed cohort of NBS CF infants 
managed with standard UK care is encouraging.  
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TABLES 
Table 1.Comparison of lung function and nutritional outcomes in infants with Cystic 
Fibrosis and healthy controls at approximately 2 years  
 Cystic Fibrosis Healthy Controls Difference (95% CI) p 
N 62 34   
Age at test, weeks 95.0 (7.3) 96.2 (7.7) -1.24 (-4.39 to 1.92) 0.44 
zHeight  0.48 (1.00) 0.71 (1.18) -0.23 (-0.69 to 0.22) 0.31 
zWeight  0.24 (0.92) 0.40 (0.86) -0.16 (-0.54 to 0.22) 0.41 
zBMI  -0.07 (0.92) -0.03 (0.90) -0.04 (-0.42 to 0.35) 0.85 
zLCI 0.78 (0.93) -0.03 (0.64) 0.81 (0.45 to 1.17) 0.001 
zFRCpleth 0.85 (1.30) 0.16 (1.28) 0.69 (0.11 to 1.26) 0.02 
zFEV0.5  -0.35 (1.00) -0.14 (1.23) -0.21 (-0.71 to 0.29) 0.41 
zFVC  -0.19 (0.94) 0.04 (0.92) -0.23 (-0.66 to 0.21) 0.3 
zFEF25–75  -0.41 (0.95) -0.24 (1.15) -0.17 (-0.64 to 0.3) 0.48 
 
Footnote: Values are mean (SD). For number of subjects with each outcome at each test 
occasion see Table E2 (OLS). Although not primary outcomes, FVC and FEF25-75 results are 
included in this table to allow comparison with the published literature. 
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Table 2: Comparison of changes (∆) in lung function and nutritional outcomes over time in 
infants with Cystic Fibrosis and healthy controls during the second year of life.  
 
 Cystic Fibrosis Healthy Controls Difference (95% CI): CF-HC 
Test interval (weeks) 42.2 (7.8) 42.8 (8.2) -0.6 (-4.1 to 2.8) 
∆zHeight  -0.04 (0.47) -0.05 (0.54) 0.01 (-0.2 to 0.22) 
∆zWeight  -0.08 (0.46) -0.05 (0.43) -0.03 (-0.22 to 0.16) 
∆zBMI  -0.10 (0.61) -0.06 (0.78) -0.05 (-0.34 to 0.24) 
∆zLCI  0.00 (1.37)  -0.15 (0.83) 0.15 (-0.39 to 0.69) 
∆zFRCpleth 0.02 (1.13)  0.01 (1.10) 0.01 (-0.5 to 0.52) 
∆zFEV0.5  0.19 (1.03)  -0.20 (1.19) 0.39 (-0.12 to 0.90) 
 
Footnote: Results are presented as the mean (SD) change in z-score for each outcome, 
between testing at ~1yr and ~2yrs. For number of subjects with each outcome, see Table E2 
(OLS). Similar comparisons of changes between 3mth to 1yr,  and 3mth to 2yr, are shown in 
Table E5 (OLS). 
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Table 3. Proportion of NBS CF infants with ‘normal’ or ‘abnormal’ results on each test occasion, and on more than one test occasion.   
 
3mth 1yr 2yr 3mth&1yr 3mth&2yr 1yr&2yr 
All test 
occasions 
Total n with LCI 57 59 61 54 56 58 53 
Normal LCI 48 (84%) 49 (83%) 52 (85%) 41 (76%) 39 (70%) 41 (71%) 34 (64%) 
Abnormal LCI 9 (16%) 10 (17%) 9 (15%) 5 (9%) 1 (2%) 2 (3%) 0 (0%) 
Total n with FRCpleth 50 59 57 47 47 54 44 
Normal FRCpleth 41 (82%) 49 (83%) 46 (81%) 35 (74%) 31 (66%) 38 (70%) 27 (61%) 
Abnormal FRCpleth 9 (18%) 10 (17%) 11 (19%) 4 (9%) 4 (9%) 3 (6%) 2 (5%) 
Total n with FEV0.5 59 58 56 56 53 54 52 
Normal FEV0.5 51 (86%) 54 (93%) 52 (93%) 46 (82%) 43 (81%) 46 (85%) 39 (75%) 
Abnormal FEV0.5 8 (14%) 4 (7%) 4 (7%) 1 (2%) 0 (0%) 0 (0%) 0 (0%) 
Total n with results from all
*
 47 57 54 44 41 51 39 
All Normal
*
 27 (57%) 36 (63%) 35 (65%) 23 (52%) 14 (34%) 20 (39%) 12 (31%) 
All Abnormal
*
 0 (%) 0 (%) 0 (%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Footnote: 
*
All= LCI, FRCpleth and FEV0.5. ‘Abnormal’ and ‘normal’ defined on basis of 1.96 z score threshold for LCI and FRCpleth, and -1.96 for 
FEV0.5. 
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FIGURES 
Figure 1. Lung function across the first two years of life in healthy infants and those with 
CF.  
A. LCI  
 
 
B. FRCpleth 
 
 
C. FEV0.5 
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Figure 1 Legend: Data plotted represent mean (95% confidence interval) z-score at the 3 
month, 1 year and 2 year test occasions for LCI (A), FRCpleth (B) and FEV0.5 (C). Open circles 
represent NBS infants with CF, triangles represent healthy controls. Limits of normality are 
represented by the dashed lines at +/- 1.96 z-scores. More detailed results, together with 
the comparison between CF and controls at each time point are presented in Table 1 and 
Table E3 (OLS). 
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Figure 2. Comparison of within-subject change for LCI over the first two years of life in healthy 
controls, in CF infants without Pseudomonas aeruginosa (PsA), and in CF infants in whom PsA had 
been isolated on at least one occasion prior to their 2yr infant lung function test.  
 
 
Figure 2 legend: Each subject is represented by an individual line. Z-scores for LCI are 
plotted against actual age at lung function test. Limits of normality are represented by the 
dashed lines at +/- 1.96 z-scores. Infants with cystic fibrosis are separated according to PsA 
status at the time of their 2 year infant lung function test (‘CF PsA’ = isolated PsA in culture 
on at least one occasion by their two year test). Similar plots for FRCpleth and FEV0.5 and for 
change over time according to whether the child had received intravenous antibiotics by 
their 2yr test are presented in Fig E2(OLS). 
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Figure 1. Lung function across the first two years of life in healthy infants and those with CF. Data 
plotted represent mean (95% confidence interval) z-score at the 3 month, 1 year and 2 year test occasions 
for LCI (A), FRCpleth (B) and FEV0.5 (C). Open circles represent NBS infants with CF, triangles represent 
healthy controls. Limits of normality are represented by the dashed lines at +/- 1.96 z-scores. More detailed 
results, together with the comparison between CF and controls at each time point are presented in Table 1 
and Table E3 (OLS).  
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Figure 2. Comparison of within-subject change for LCI over the first two years of life in healthy 
controls, in CF infants without Pseudomonas aeruginosa (PsA), and in CF infants in whom PsA 
had been isolated on at least one occasion prior to their 2yr infant lung function test. 
Each subject is represented by an individual line. Z-scores for LCI are plotted against actual age at lung 
function test. Limits of normality are represented by the dashed lines at +/- 1.96 z-scores. Infants with 
cystic fibrosis are separated according to PsA status at the time of their 2 year infant lung function test (‘CF 
PsA’ = isolated PsA in culture on at least one occasion by their two year test). Similar plots for FRCpleth and 
FEV0.5 and for change over time according to whether the child had received intravenous antibiotics by their 
2yr test are presented in Fig E2(OLS).  
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Table E1a. Study population and background demographics 
 CF (n=62) Healthy controls 
(n=34) 
Δ (95% CI) CF– controls 
Male  29 (47%) 17 (50%)  
Gestational age (GA), 
weeks  
39.1 (1.5) 40.4 (1.2) -1.21 (-1.81 to -0.61) 
Birth weight*, z-score -0.5 (1.0) 0.2 (0.8) -0.69 (-1.09 to -0.28) 
White mother  55 (89%) 30 (88%)  
Cystic fibrosis infants only 
Postnatal age at 
diagnosis (weeks)$  
3.7(3.3-4.4)  
p.Phe508del**, n= 60  54 (90%) 
Presented with 
meconium ileus  
8 (12.9%) 
Pancreatic sufficient  6 (9.7%) 
Results presented as n(%) or mean(SD) unless stated otherwise. *z-scores calculated according to 
Cole et al [E1] (infants with GA <37 weeks calculated using UK-WHO-preterm;  ≥37 weeks UK-WHO-
term). **homozygous or heterozygous. $median(interquartile range).  
Table E1b: Additional clinical details for CF Infants in relation to test occasion 
 By 1yr test (n=60) By 2yr test (n=62) 
Respiratory symptoms  
Physician diagnosed 
wheeze (ever) 
20/60 (34%)  25/62 (40%) 
Additional treatment (n(%))  
rhDNase (ever) 6/59 (10%) 9/51 (18%) 
IV antibiotics (ever) 16/60 (27%)  27/58(47%) 
Gastroesophageal reflux 
disease treatment 
29/56 (52%) 31/61 (51%) 
Airway microbiology (ever)  
Pseudomonas aeruginosa  19 (31%), n=1 chronic 32/62 (52%), n=4 chronic 
Staph aureus  10 (16%) 18 (29%), n=1 chronic 
Haemophilus influenza 15 (24%) 21 (34%) 
 
Of the 27 children who had received intravenous (IV) antibiotics by their two year test, 22 
(81%) had isolated Pseudomonas aeruginosa (PsA) on at least one occasion. All nine children 
who had received nebulised rhDNase by the 2yr test had also received at least one course of 
IV antibiotics. Fourteen children received IV antibiotics between their 1yr and 2yr test.  
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Table E2. Technically satisfactory infant lung function results on each test occasion  
 3 months 1 year 2 years 1yr & 2yr 3mth & 2yr 
CF (n=61) Controls 
(n=33) 
CF 
(n=60) 
Controls 
(n=32) 
CF 
(n=62) 
Controls 
(n=34) 
CF 
(n=60) 
Controls 
(n=32) 
CF 
(n=61) 
Controls 
(n=33) 
LCI 57 (93) 30 (91) 59 (98) 32 (100) 61 (98) 33 (97) 58 (97) 31 (97) 56 (92) 29 (88) 
FRCpleth 50 (82) 29 (88) 59 (98) 32 (100) 57 (92) 31 (91) 54 (90) 30 (94) 47 (77) 26 (79) 
FEV0.5 59 (97) 32 (97) 58 (97) 32 (100) 56 (90) 28 (82) 54 (90) 27 (84) 53 (87) 27 (82) 
 
Results are presented as n (%) successful measurements according to outcome. 
Abbreviations: LCI= lung clearance index; FRCpleth = plethysmographic functional residual capacity; FEV0.5= forced expiratory volume in 0.5 
seconds. 
Of the 62 CF infants tested at ~2year, all been assessed previously on at least one occasion (61 at 3 months and 60 at 1 year). Similarly, of the 
34 healthy infants studied at ~2yr, 33 had been tested at 3mth and 32 at 1yr.  Technically satisfactory results in all three infant lung function 
outcomes (LCI, FRCpleth and FEV0.5) were obtained in 47 CF infants at 3mths, 57 at 1yr and 54 at the 2 year test occasion.  
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Comparison of previously reported outcomes at 3 months and 1 year for the NBS cohort 
Recently published equations for the calculation of z-scores from the RVRTC technique have 
improved the confidence with which we can accurately detect and quantify abnormality in 
infant lung function (ILF) tests [E2, E3], particularly for infants in the first few months of life. As 
these new equations have been used for analyses presented within this paper, a comparison 
with our previously published results obtained using older equations [E4] was undertaken. 
Cross sectional results for CF infants and controls at 3mth and 1yr were largely consistent with 
previous reports [E5, E6, E7, E8]. Minor discrepancies using the new equations included mean 
FEV0.5 in CF infants being slightly less ‘abnormal’ at three months of age. 
Had we applied the reference equations described by Lum et al [E4], the mean(SD) FEV0.5 at 
3mth for the infants included in this 2yr follow –up  would have been -1.20(1.05) z-scores, 
rather than - 0.86 (0.99) as detailed in Table E3. This is virtually identical to the FEV0.5 at 3mth 
originally reported both for the entire NBS LCFC cohort and for those followed up to 1yr of 
age[E6, E7] where these equations were used.  
Hoo et al reported that at 3mths of age, 25% of CF infants (17/68) had an abnormally low FEV0.5 
(below -1.96 z-scores) [E6]. Had we used the Lum equations [E4] as applied by Hoo et al, 14/59 
(24%) of CF infants in this 2yr cohort would have had an abnormal FEV0.5 at 3mths. This suggests 
that those followed up to two years were representative of the original cohort recruited. When 
using the updated reference equations, only 8/59 (14%) of CF infants had abnormal FEV0.5 at 
3mths. Nevertheless, despite this shift in absolute z-scores resulting from use of updated 
equations, the differences in ILF between the CF and control group reported previously and in 
Page 35 of 72 European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 5 
 
this current paper remain unchanged (Hoo et al reported a mean difference of 0.92 (1.29 to 
0.56) z-scores between CF and HC at 3 months, which is virtually identical to that shown below 
in Table E3 when using the updated equations.
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Table E3. Comparison of lung function in infants with CF and healthy controls at 
approximately 3 months (A) and 1 year (B) of age 
 
A 
 Cystic Fibrosis Healthy Control Difference (95% CI) p 
N 61 33   
Age at test, weeks 11.2 (2.4) 12.3 (2.1) -1.05 (-2.04 to -0.07) 0.04 
zHeight  -0.21 (1.07) 0.83 (0.80) -1.04 (-1.46 to -0.62) <0.001 
zWeight  -0.97 (1.09) -0.04 (0.89) -0.93 (-1.37 to -0.49) <0.001 
zBMI  -1.20 (0.94) -0.69 (0.99) -0.51 (-0.92 to -0.10) 0.02 
zLCI  0.62 (1.24) 0.28 (0.89), 0.34 (-0.17 to 0.85) 0.19 
zFRCpleth 0.79 (1.14) -0.18 (1.07) 0.97 (0.45 to 1.49) <0.001 
zFEV0.5  -0.86 (0.99) 0.08 (0.84) -0.94 (-1.36 to -0.53) <0.001 
zFVC  -0.97 (1.25) -0.16 (0.94) -0.81 (-1.31 to -0.31) 0.002 
zFEF25–75  -0.75 (1.16) 0.24 (0.98) -0.99 (-1.47 to -0.51) <0.001 
 
B.  
 Cystic Fibrosis Healthy Control Difference (95% CI) p 
N 60 32   
Age at test, weeks 52.8 (5.3) 53.8 (3.4) -1.05 (-3.09 to 0.99) 0.31 
zHeight  0.47 (0.97) 0.74 (1.09) -0.26 (-0.71 to 0.18) 0.24 
zWeight  0.26 (0.87) 0.44 (0.99) -0.18 (-0.57 to 0.22) 0.38 
zBMI  -0.01 (0.74) 0.03 (0.83) -0.04 (-0.38 to 0.29) 0.80 
zLCI  0.82 (1.16) 0.13 (0.87) 0.69 (0.22 to 1.15) 0.004 
zFRCpleth 0.82 (1.2) 0.14 (1.21) 0.69 (0.16 to 1.21) 0.01 
zFEV0.5  -0.51 (1.04) 0.13 (0.88) -0.64 (-1.07 to -0.21) 0.004 
zFVC  -0.51 (1.03) 0.24 (0.94) -0.75 (-1.19 to -0.31) 0.001 
zFEF25–75  -0.29 (1.15) -0.01 (0.99) -0.28 (-0.76 to 0.2) 0.25 
 
Footnote: Values are mean (SD). For number of subjects with lung function outcome at each 
test occasion see Table E2 OLS. Although not a primary outcome, FVC and FEF25-75 results are 
included in this table to allow comparison with the published literature. 
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Table E4: Change in lung function z-scores between test occasions in A) infants with CF and B) 
control infants.  
A) Cystic Fibrosis Mean (SD) 
difference 
95% CI of the 
Difference 
p 
LCI 
3 months to 1 year 0.33 (1.19) 0.00 to 0.65 0.050 
3 months to 2 years 0.16 (1.51) -0.24 to 0.57 0.427 
1 year to 2 years  0.00 (1.37) -0.36 to 0.36 0.993 
FRCpleth 
3 months to 1 year 0.04 (1.19) -0.31 to 0.38 0.836 
3 months to 2 years 0.08 (1.38) -0.33 to 0.48 0.707 
1 year to 2 years  0.02 (1.13) -0.29 to 0.33 0.901 
FEV0.5 
3 months to 1 year 0.36 (0.97) 0.10 to 0.62 0.008 
3 months to 2 years 0.46 (1.13) 0.15 to 0.78 0.004 
1 year to 2 years  0.19 (1.03) -0.09 to 0.47 0.179 
 
B) Healthy controls Mean (SD) 
difference 
95% CI of the 
Difference 
p 
LCI 
3 months to 1 year -0.10 (1.14) -0.54 to 0.35 0.659 
3 months to 2 years -0.16 (0.83) -0.48 to 0.15 0.296 
1 year to 2 years  -0.15 (0.83) -0.46 to 0.16 0.327 
FRCpleth 
3 months to 1 year 0.29 (1.59) -0.34 to 0.92 0.348 
3 months to 2 years 0.42 (1.58) -0.22 to 1.06 0.186 
1 year to 2 years  0.01 (1.10) -0.40 to 0.42 0.967 
FEV0.5 
3 months to 1 year -0.02 (0.89) -0.35 to 0.31 0.901 
3 months to 2 years -0.23 (1.11) -0.67 to 0.21 0.290 
1 year to 2 years  -0.20 (1.19) -0.67 to 0.27 0.386 
 
Footnote: As can be seen, in contrast to infants with CF in whom LCI deteriorated between 
3mth and 1yr, FEV0.5 improved between both 3mth and 1yr and between 1yr and 2yrs. There 
were no significant group changes in any infant lung function outcome over time among the 
control infants. 
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Table E5: Comparison of changes (∆) in lung function and nutritional outcomes over time in infants with cystic fibrosis (CF) and 
healthy controls (HC) between approximately 3 months and 1 year, and between 3 months to 2 years of age.  
 
 3 months to 1 year 3 months to 2 years 
 Cystic Fibrosis Healthy 
controls 
Difference in change 
(95% CI) 
Cystic 
Fibrosis 
Healthy 
controls 
Difference in change 
(95% CI) 
Interval 
(weeks) 
41.6 (5.0) 41.5 (3.8) 0.1 (-1.9 to 2.1) 83.7 (7.8) 83.7 (7.7) 0.1 (-3.3 to 3.4) 
∆ zHeight  0.75 (0.70) -0.07 (0.71) 0.82 (0.51 to 1.13) ** 0.69 (0.89) -0.1 (0.91) 0.79 (0.41 to 1.18)** 
∆ zWeight  1.30 (0.80) 0.46 (0.79) 0.84 (0.49 to 1.19) ** 1.21 (1.02) 0.46 (0.84) 0.75 (0.34 to 1.16)** 
∆ zBMI  1.23 (0.89) 0.68 (0.92) 0.55 (0.15 to 0.95) ** 1.12 (1.15) 0.67 (1.22) 0.45 (-0.06 to 0.95) 
∆ zLCI  0.33 (1.19) -0.10 (1.14) 0.42 (-0.12 to 0.97) 0.16 (1.51) -0.16 (0.83) 0.33 (-0.27 to 0.93) 
∆ zFRCpleth 0.03 (1.19) 0.29 (1.59) -0.26 (-0.91 to 0.39) 0.08 (1.38) 0.42 (1.58) -0.34 (-1.05 to 0.36) 
∆ zFEV0.5  0.36 (0.97) -0.02 (0.89) 0.38 (-0.04 to 0.80) 0.46 (1.13) -0.23 (1.11) 0.70 (0.17 to 1.23)* 
 
Footnote: Results are presented as the mean (SD) change in z-score for each outcome, between testing at approximately   3 months and either 1 
or 2 years of age. *p<0.05, **p<0.01. For number of subjects with each outcome, see table E2. The comparison of changes in lung function and 
nutritional outcomes over time in infants with Cystic Fibrosis and healthy controls during the second year of life is presented in the main MS 
(Table 2).  
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The association of lung function results between different test occasions for each of the primary 
outcomes is shown in Fig E1. In contrast to the highly significant relationship in both FRCpleth and 
FEV0.5 across all test occasions in infants with CF, LCI at 2yr was not predicted by that measured 
at either 3mth or 1yr. Of note, the majority of ILF results for CF infants remained within the 
normal range at both 1 and 2yrs. Of the 10 CF infants with an abnormal LCI at 1yr, all but two 
had a result within the normal range by ~2yr (Fig 3 and E1). Similarly, only 2/9 infants with 
abnormal LCI at 2yr also had an abnormal 1yr result.  No child had an abnormal LCI on all three 
occasions (Table 3, main manuscript). Similarly, the majority of CF infants with abnormal FRCpleth 
at 2yrs had had normal results at 1yr and vice versa (Fig 3 and E1) with only two children having 
abnormal zFRCpleth on all test occasions. No child with abnormal  zFEV0.5 at ~2yr had had 
abnormal results at either 3mth or 1yr (Fig 3 and E1). 
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Figure E1. Relationship of results between test occasions within each lung function outcome 
in infants and young children with CF (A) and in healthy controls (B).   
A. Cystic Fibrosis    B. Healthy controls 
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A. Cystic Fibrosis    B. Healthy controls 
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A. Cystic Fibrosis    B. Healthy controls 
 
 
 
 
  
 
 
Legend: Relationship of LCI, FRCpleth, and FEV0.5 between various test occasions in children with 
CF and healthy infants. For each outcome, all subjects with results on both test occasions are 
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represented by an individual data point. Limits of normality are shown at 1.96 z-scores for LCI 
and FRCpleth, and -1.96z for FEV0.5. The between-test equivalence line is shown on each cross-
plot as a dashed line. For LCI and FRCpleth, all values to the right of the vertical line or above the 
horizontal cut-off were abnormal. Those in the right upper shaded quadrant were abnormal on 
both occasions (e.g. n=2 subjects with CF for LCI and n=3 with CF for FRCpleth at 2yrs). For FEV0.5, 
values to the left of the vertical line or below the horizontal cut-off were abnormal. The one CF 
infant with abnormal FEV0.5 at both 3 months  and 1 year appears in the shaded left lower 
quadrant. 
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Fig E2. Within-subject variability for infant lung function outcomes in healthy controls, and for 
CF infants according to whether they had ever isolated Pseudomonas aeruginosa, or received 
any IV antibiotics by their 2yr infant lung function test.  
 
LCI 
 
             Control     CF, No PsA CF PsA           Control              CF, No IVAB         CF IVAB
  
 
 
 
FRCpleth 
 
             Control       CF, No PsA   CF PsA                              Control         CF, No IVAB            CF IVAB 
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FEV0.5 
               Control                 CF, No PsA        CF PsA   Control               CF, No IVAB            CF IVAB 
  
 
Legend: Each subject is represented by an individual line. Z-scores for each infant lung function 
(ILF) test (LCI, FRCpleth and FEV0.5) are plotted against actual age at test. Limits of normality are 
represented by the dashed lines at +/- 1.96 z-scores. For infants with cystic fibrosis, plots are 
separated according to Pseudomonas aeruginosa (PsA) status (left hand panel) or whether they 
had ever received intravenous antibiotics (IVAB) (right hand panel) by their 2yr lung function 
test at ~2 years. Infants with CF were considered ‘CF PsA’ if they had ever isolated PsA in culture 
by their 2yr ILF. Control infants are represented on the left of both panels for ease of 
comparison. As can be seen, while there was a tendency for those with an abnormally high LCI 
during the first year of life to improve by 2 years, whereas most infants with abnormal LCI by 2 
years had results within the normal range previously,  no clear pattern was evident.   
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Fig E3. Change in LCI between ~1 and ~2yrs of life plotted against age at final (~2yr) test, 
classified according to Pseudomonas aeruginosa status (A), or treatment with at least one 
course of intravenous antibiotics by final lung function test (B). 
A. Pseudomonas aeruginosa status 
 
B. Intravenous antibiotics 
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Legend: CF infants with LCI measurements at 1 & 2yrs of age are represented with one data 
point per subject. NOTE: In contrast to spirometric outcomes, an increase in zLCI between tests 
is suggestive of deterioration whereas a decrease is suggestive of improvement. Infants with CF 
are classified according to Pseudomonas aeruginosa (PsA) status (A), or treatment with at least 
one course of intravenous (IV) antibiotics by final lung function test (B). In plot A, Infants with 
CF but no isolations of PsA by their ~2year lung function tests are represented by open circles. 
Infants isolating PsA on at least one occasion by their final test are represented by grey filled 
circles. In plot B, infants with CF with no history of ever receiving IV antibiotics by their ~2year 
lung function tests are represented by open circles. Infants with at least one course of IV 
antibiotics by their final test are represented by grey filled circles.  
 
 
 
 
There was no relationship between the magnitude or direction of change in LCI between ~1 and ~2 years 
of life and age at which the final (~2yr) test was performed, nor with either Pseudomonas aeruginosa 
status or history of IV antibiotics by the time of the final ILF visit (Fig E3 and Table E6). While the 
improvement in FEV0.5 during the first year of life was significantly greater in CF infants who did not 
isolate PsA during this period, than in those that did, catch up in the latter group was faster during the 
second year of life (Table E6). 
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Table E6. Comparison of changes (∆) in lung function over time in infants with cystic fibrosis 
(CF) between test dates according to history of Pseudomonas aeruginosa (PsA), (A) or 
intravenous (IV) antibiotics (B) by final (~2year) infant lung function test. 
A) Pseudomonas aeruginosa (ever by 2yr test) 
 3months to 1year 
 CF PsA CF No PsA Difference in change (95% CI) 
∆ zLCI  0.17(1.12), n=29 0.50(1.28), n=25 -0.33(-0.98 to 0.32) 
∆ zFRCpleth 0.07(1.16), n=26 0.00(1.24), n=21 0.07 (-0.63 to 0.78) 
∆ zFEV0.5  0.11(1.07), n=30 0.64(0.76), n=26 -0.53(-1.03 to -0.02)* 
 1 year to 2 years 
 CF PsA CF No PsA Difference in change (95% CI) 
∆ zLCI  0.08(1.56), n=30 -0.09(1.16), n=28 0.17(-0.56 to 0.90) 
∆ zFRCpleth 0.11(1.25), n=30 -0.09(0.98), n=24 0.20(-0.43 to 0.82) 
∆ zFEV0.5  0.38(1.16), n=30 -0.05(0.82), n=24 0.43(-0.13 to 0.99) 
 3months to 2 years 
 CF PsA CF No PsA Difference in change (95% CI) 
∆ zLCI  0.05(1.76), n=29 0.28(1.20), n=27 -0.23(-1.04 to 0.59) 
∆ zFRCpleth 0.34(1.35), n=25 -0.22(1.37), n=22 0.56 (-0.24 to 1.36) 
∆ zFEV0.5  0.43(1.25), n=29 0.51(1.00), n=24 -0.08 (-0.71 to 0.55) 
 
B. IV antibiotics (ever by 2 yr test) 
 3months to 1year 
 CF IVABs CF No IVABs Difference in change (95% CI) 
∆ zLCI  0.48 (1.09), n=23 0.29 (1.30), n=27 0.19 (-0.50 to 0.88) 
∆ zFRCpleth -0.02 (1.20), n=22 0.11 (1.08), n=22 -0.14 (-0.83 to 0.56) 
∆ zFEV0.5  0.22 (1.07), n=25 0.51 (0.90), n=27 -0.29 (-0.84 to 0.27) 
 1 year to 2 years 
 CF IVABs CF No IVABs Difference in change (95% CI) 
∆ zLCI  -0.33 (1.22), n=25 0.2 (1.48), n=30 -0.53 (-1.27 to 0.22) 
∆ zFRCpleth 0.04 (1.28), n=24 -0.03 (1.07), n=27 0.07 (-0.59 to 0.73) 
∆ zFEV0.5  0.41 (1.02), n=24 0.05 (1.07), n=26 0.36 (-0.24 to 0.96) 
 3months to 2 years 
 CF IVABs CF No IVABs Difference in change (95% CI) 
∆ zLCI  -0.10 (1.59), n=24 0.42 (1.51), n=28 -0.52 (-1.39 to 0.34) 
∆ zFRCpleth 0.18 (1.27), n=21 0.01 (1.45), n=22 0.18 (-0.67 to 1.02) 
∆ zFEV0.5  0.58(1.13), n=24 0.43(1.18), n=25 0.16 (-0.51 to 0.82) 
Footnote: Results are presented as the mean (SD) change in z-score for each outcome, between testing 
at approximately   3 months and 1 year, 1 year to 2 years, and 3months to 2 years of age. Numbers (n) 
for each unpaired t-test comparison are shown.  *p<0.05.  
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Sample calculations for randomised control trials (RCTs). 
The results from the current study indicate that, contrary to our previous suggestions [E6, E7], when 
studying a NBS cohort of infants with CF managed according to standard UK protocols, it is not possible 
to identify infants who are at high-risk ‘ for poor lung function by 2 years of age for selective recruitment 
into an RCT. The impact that this would have on power calculations for studies intending to use infant 
LFT as an outcome variable in the first 2 years of life is explained below in two  excerpts from Nguyen et 
al Thorax 2014, which presented results from this cohort at 1yr of age. 
Excerpt from discussion in main MS: Nguyen et al 2014 [E7] 
Using data from this study, results from ∼85 infants/arm would be required to detect relatively small 
differences in lung function (ie, equivalent to 0.5 z-scores) that might occur in response to an 
intervention if unselected NBS CF were recruited to such a trial. By contrast, were recruitment to such a 
RCT limited to a ‘high-risk group’ (ie, abnormal PFTs by 3 months, see online supplementary tables E3 
and E4), a larger treatment effect would be expected, with only 22 infants/arm being required to detect 
a difference of 1 z-score (equivalent to ∼9% for LCI), with 90% power. Such an approach could optimise 
recruitment since parents of infants with early PFT abnormalities would be more likely to consent, and 
also this approach would minimise exposure of children with potentially little to gain from therapy from 
unnecessary side effects. 
 
From Nguyen et al  2014; OLS Section e [E7] 
Sample size calculations depend on numerous factors including the magnitude of change/difference to 
be detected, the number of outcomes under investigation, the between subject variability for any given 
outcome, and the confidence (power) that is desired with which to detect such differences. Taking into 
account the between-subject variability of infant PFTs observed in this and previously published 
studies[E5-7] a difference of 1 z-score (SD) at 1 year equates to ~ 9% or 0.64 units for LCI, 14.5% or 27 
mL for FRCpleth and 15% or 46 mL for FEV0.5. Decisions regarding what constitutes a minimal clinically 
important difference in intervention trials are complex, but values equating to at least 0.5 SD (or z16 
scores) are probably appropriate, to avoid risk of sampling error.[E9] In contrast to studies in older 
children with CF, in whom larger differences in PFTs may be observed,[E10] the mean difference 
between the NBS CF infants and healthy controls at one year for the 3 primary outcomes in this study 
was only 0.5 to 0.8 z-scores (with 95% confidence intervals ranging between 0.2 – 1.2 z-scores, Table 2, 
main manuscript). 
If planning a randomised controlled intervention study with, for example, LCI as a primary endpoint, a 
sample size of 85 subjects per arm would allow detection of differences in lung function at one year of 
age equivalent to 0.5 z-scores at the 5% significance level with 90% power, whereas 63 patients per 
group would provide 80% power to detect the same difference.[E11-13] Given that, despite excellent 
success rates in PFTs and minimal attrition, paired lung function tests at 1 year were ‘only’ attained in 
62% NBS CF infants presenting during the recruitment period (Figure 1), a pool of at least 275 CF infants 
(85 x2 x100/62) would be required to undertake such a study, increasing further if based on more than 
one outcome. However, if recruitment were limited to those with evidence of abnormal lung function at 
3 months, then the magnitude for potential improvement would be considerably larger. Under these 
circumstances, an effective intervention in this ‘high risk group’ could improve lung function by at least 1 
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z-score (Table E4 and E5). Thus a RCT designed to detect a 1 z-score improvement in lung function in 
response to an intervention would only require 22 infants in each arm for 90% power at the 5% 
significance level. Nevertheless, since abnormalities at 3 months were only observed in 30% of our 
infants when based on the 2 most feasible PFTs (LCI and FEV0.5), after allowing for attrition and 
exclusions as discussed above it would still be necessary to access a population of (22 x 2) x (100/62) x 
(100/30) i.e. ~237 NBS CF infants to obtain 90% power in a RCT. This is more than double the number 
identified in the South-East of England over a 2.5 year period during the present study and would hence 
inevitably require a multi-centre study if to be completed in a timely manner. 
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Table E1a. Study population and background demographics 
 CF (n=62) Healthy controls 
(n=34) 
Δ (95% CI) CF– controls 
Male  29 (47%) 17 (50%)  
Gestational age (GA), 
weeks  
39.1 (1.5) 40.4 (1.2) -1.21 (-1.81 to -0.61) 
Birth weight*, z-score -0.5 (1.0) 0.2 (0.8) -0.69 (-1.09 to -0.28) 
White mother  55 (89%) 30 (88%)  
Cystic fibrosis infants only 
Postnatal age at 
diagnosis (weeks)$  
3.7(3.3-4.4)  
p.Phe508del**, n= 60  54 (90%) 
Presented with 
meconium ileus  
8 (12.9%) 
Pancreatic sufficient  6 (9.7%) 
Results presented as n(%) or mean(SD) unless stated otherwise. *z-scores calculated according to 
Cole et al [E1] (infants with GA <37 weeks calculated using UK-WHO-preterm;  ≥37 weeks UK-WHO-
term). **homozygous or heterozygous. $median(interquartile range).  
Table E1b: Additional clinical details for CF Infants in relation to test occasion 
 By 1yr test (n=60) By 2yr test (n=62) 
Respiratory symptoms  
Physician diagnosed 
wheeze (ever) 
20/60 (34%)  25/62 (40%) 
Additional treatment (n(%))  
rhDNase (ever) 6/59 (10%) 9/51 (18%) 
IV antibiotics (ever) 16/60 (27%)  27/58(47%) 
Gastroesophageal reflux 
disease treatment 
29/56 (52%) 31/61 (51%) 
Airway microbiology (ever)  
Pseudomonas aeruginosa  19 (31%), n=1 chronic 32/62 (52%), n=4 chronic 
Staph aureus  10 (16%) 18 (29%), n=1 chronic 
Haemophilus influenza 15 (24%) 21 (34%) 
 
Of the 27 children who had received intravenous (IV) antibiotics by their two year test, 22 
(81%) had isolated Pseudomonas aeruginosa (PsA) on at least one occasion. All nine children 
who had received nebulised rhDNase by the 2yr test had also received at least one course of 
IV antibiotics. Fourteen children received IV antibiotics between their 1yr and 2yr test.  
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Table E2. Technically satisfactory infant lung function results on each test occasion  
 3 months 1 year 2 years 1yr & 2yr 3mth & 2yr 
CF (n=61) Controls 
(n=33) 
CF 
(n=60) 
Controls 
(n=32) 
CF 
(n=62) 
Controls 
(n=34) 
CF 
(n=60) 
Controls 
(n=32) 
CF 
(n=61) 
Controls 
(n=33) 
LCI 57 (93) 30 (91) 59 (98) 32 (100) 61 (98) 33 (97) 58 (97) 31 (97) 56 (92) 29 (88) 
FRCpleth 50 (82) 29 (88) 59 (98) 32 (100) 57 (92) 31 (91) 54 (90) 30 (94) 47 (77) 26 (79) 
FEV0.5 59 (97) 32 (97) 58 (97) 32 (100) 56 (90) 28 (82) 54 (90) 27 (84) 53 (87) 27 (82) 
 
Results are presented as n (%) successful measurements according to outcome. 
Abbreviations: LCI= lung clearance index; FRCpleth = plethysmographic functional residual capacity; FEV0.5= forced expiratory volume in 0.5 
seconds. 
Of the 62 CF infants tested at ~2year, all been assessed previously on at least one occasion (61 at 3 months and 60 at 1 year). Similarly, of the 
34 healthy infants studied at ~2yr, 33 had been tested at 3mth and 32 at 1yr.  Technically satisfactory results in all three infant lung function 
outcomes (LCI, FRCpleth and FEV0.5) were obtained in 47 CF infants at 3mths, 57 at 1yr and 54 at the 2 year test occasion.  
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Comparison of previously reported outcomes at 3 months and 1 year for the NBS cohort 
Recently published equations for the calculation of z-scores from the RVRTC technique have 
improved the confidence with which we can accurately detect and quantify abnormality in 
infant lung function (ILF) tests [E2, E3], particularly for infants in the first few months of life. As 
these new equations have been used for analyses presented within this paper, a comparison 
with our previously published results obtained using older equations [E4] was undertaken. 
Cross sectional results for CF infants and controls at 3mth and 1yr were largely consistent with 
previous reports [E5, E6, E7, E8]. Minor discrepancies using the new equations included mean 
FEV0.5 in CF infants being slightly less ‘abnormal’ at three months of age. 
Had we applied the reference equations described by Lum et al [E4], the mean(SD) FEV0.5 at 
3mth for the infants included in this 2yr follow –up  would have been -1.20(1.05) z-scores, 
rather than - 0.86 (0.99) as detailed in Table E3. This is virtually identical to the FEV0.5 at 3mth 
originally reported both for the entire NBS LCFC cohort and for those followed up to 1yr of 
age[E6, E7] where these equations were used.  
Hoo et al reported that at 3mths of age, 25% of CF infants (17/68) had an abnormally low FEV0.5 
(below -1.96 z-scores) [E6]. Had we used the Lum equations [E4] as applied by Hoo et al, 14/59 
(24%) of CF infants in this 2yr cohort would have had an abnormal FEV0.5 at 3mths. This suggests 
that those followed up to two years were representative of the original cohort recruited. When 
using the updated reference equations, only 8/59 (14%) of CF infants had abnormal FEV0.5 at 
3mths. Nevertheless, despite this shift in absolute z-scores resulting from use of updated 
equations, the differences in ILF between the CF and control group reported previously and in 
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this current paper remain unchanged (Hoo et al reported a mean difference of 0.92 (1.29 to 
0.56) z-scores between CF and HC at 3 months, which is virtually identical to that shown below 
in Table E3 when using the updated equations.
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Table E3. Comparison of lung function in infants with CF and healthy controls at 
approximately 3 months (A) and 1 year (B) of age 
 
A 
 Cystic Fibrosis Healthy Control Difference (95% CI) p 
N 61 33   
Age at test, weeks 11.2 (2.4) 12.3 (2.1) -1.05 (-2.04 to -0.07) 0.04 
zHeight  -0.21 (1.07) 0.83 (0.80) -1.04 (-1.46 to -0.62) <0.001 
zWeight  -0.97 (1.09) -0.04 (0.89) -0.93 (-1.37 to -0.49) <0.001 
zBMI  -1.20 (0.94) -0.69 (0.99) -0.51 (-0.92 to -0.10) 0.02 
zLCI  0.62 (1.24) 0.28 (0.89), 0.34 (-0.17 to 0.85) 0.19 
zFRCpleth 0.79 (1.14) -0.18 (1.07) 0.97 (0.45 to 1.49) <0.001 
zFEV0.5  -0.86 (0.99) 0.08 (0.84) -0.94 (-1.36 to -0.53) <0.001 
zFVC  -0.97 (1.25) -0.16 (0.94) -0.81 (-1.31 to -0.31) 0.002 
zFEF25–75  -0.75 (1.16) 0.24 (0.98) -0.99 (-1.47 to -0.51) <0.001 
 
B.  
 Cystic Fibrosis Healthy Control Difference (95% CI) p 
N 60 32   
Age at test, weeks 52.8 (5.3) 53.8 (3.4) -1.05 (-3.09 to 0.99) 0.31 
zHeight  0.47 (0.97) 0.74 (1.09) -0.26 (-0.71 to 0.18) 0.24 
zWeight  0.26 (0.87) 0.44 (0.99) -0.18 (-0.57 to 0.22) 0.38 
zBMI  -0.01 (0.74) 0.03 (0.83) -0.04 (-0.38 to 0.29) 0.80 
zLCI  0.82 (1.16) 0.13 (0.87) 0.69 (0.22 to 1.15) 0.004 
zFRCpleth 0.82 (1.2) 0.14 (1.21) 0.69 (0.16 to 1.21) 0.01 
zFEV0.5  -0.51 (1.04) 0.13 (0.88) -0.64 (-1.07 to -0.21) 0.004 
zFVC  -0.51 (1.03) 0.24 (0.94) -0.75 (-1.19 to -0.31) 0.001 
zFEF25–75  -0.29 (1.15) -0.01 (0.99) -0.28 (-0.76 to 0.2) 0.25 
 
Footnote: Values are mean (SD). For number of subjects with lung function outcome at each 
test occasion see Table E2 OLS. Although not a primary outcome, FVC and FEF25-75 results are 
included in this table to allow comparison with the published literature. 
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Table E4: Change in lung function z-scores between test occasions in A) infants with CF and B) 
control infants.  
A) Cystic Fibrosis Mean (SD) 
difference 
95% CI of the 
Difference 
p 
LCI 
3 months to 1 year 0.33 (1.19) 0.00 to 0.65 0.050 
3 months to 2 years 0.16 (1.51) -0.24 to 0.57 0.427 
1 year to 2 years  0.00 (1.37) -0.36 to 0.36 0.993 
FRCpleth 
3 months to 1 year 0.04 (1.19) -0.31 to 0.38 0.836 
3 months to 2 years 0.08 (1.38) -0.33 to 0.48 0.707 
1 year to 2 years  0.02 (1.13) -0.29 to 0.33 0.901 
FEV0.5 
3 months to 1 year 0.36 (0.97) 0.10 to 0.62 0.008 
3 months to 2 years 0.46 (1.13) 0.15 to 0.78 0.004 
1 year to 2 years  0.19 (1.03) -0.09 to 0.47 0.179 
 
B) Healthy controls Mean (SD) 
difference 
95% CI of the 
Difference 
p 
LCI 
3 months to 1 year -0.10 (1.14) -0.54 to 0.35 0.659 
3 months to 2 years -0.16 (0.83) -0.48 to 0.15 0.296 
1 year to 2 years  -0.15 (0.83) -0.46 to 0.16 0.327 
FRCpleth 
3 months to 1 year 0.29 (1.59) -0.34 to 0.92 0.348 
3 months to 2 years 0.42 (1.58) -0.22 to 1.06 0.186 
1 year to 2 years  0.01 (1.10) -0.40 to 0.42 0.967 
FEV0.5 
3 months to 1 year -0.02 (0.89) -0.35 to 0.31 0.901 
3 months to 2 years -0.23 (1.11) -0.67 to 0.21 0.290 
1 year to 2 years  -0.20 (1.19) -0.67 to 0.27 0.386 
 
Footnote: As can be seen, in contrast to infants with CF in whom LCI deteriorated between 
3mth and 1yr, FEV0.5 improved between both 3mth and 1yr and between 1yr and 2yrs. There 
were no significant group changes in any infant lung function outcome over time among the 
control infants. 
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Table E5: Comparison of changes (∆) in lung function and nutritional outcomes over time in infants with cystic fibrosis (CF) and 
healthy controls (HC) between approximately 3 months and 1 year, and between 3 months to 2 years of age.  
 
 3 months to 1 year 3 months to 2 years 
 Cystic Fibrosis Healthy 
controls 
Difference in change 
(95% CI) 
Cystic 
Fibrosis 
Healthy 
controls 
Difference in change 
(95% CI) 
Interval 
(weeks) 
41.6 (5.0) 41.5 (3.8) 0.1 (-1.9 to 2.1) 83.7 (7.8) 83.7 (7.7) 0.1 (-3.3 to 3.4) 
∆ zHeight  0.75 (0.70) -0.07 (0.71) 0.82 (0.51 to 1.13) ** 0.69 (0.89) -0.1 (0.91) 0.79 (0.41 to 1.18)** 
∆ zWeight  1.30 (0.80) 0.46 (0.79) 0.84 (0.49 to 1.19) ** 1.21 (1.02) 0.46 (0.84) 0.75 (0.34 to 1.16)** 
∆ zBMI  1.23 (0.89) 0.68 (0.92) 0.55 (0.15 to 0.95) ** 1.12 (1.15) 0.67 (1.22) 0.45 (-0.06 to 0.95) 
∆ zLCI  0.33 (1.19) -0.10 (1.14) 0.42 (-0.12 to 0.97) 0.16 (1.51) -0.16 (0.83) 0.33 (-0.27 to 0.93) 
∆ zFRCpleth 0.03 (1.19) 0.29 (1.59) -0.26 (-0.91 to 0.39) 0.08 (1.38) 0.42 (1.58) -0.34 (-1.05 to 0.36) 
∆ zFEV0.5  0.36 (0.97) -0.02 (0.89) 0.38 (-0.04 to 0.80) 0.46 (1.13) -0.23 (1.11) 0.70 (0.17 to 1.23)* 
 
Footnote: Results are presented as the mean (SD) change in z-score for each outcome, between testing at approximately   3 months and either 1 
or 2 years of age. *p<0.05, **p<0.01. For number of subjects with each outcome, see table E2. The comparison of changes in lung function and 
nutritional outcomes over time in infants with Cystic Fibrosis and healthy controls during the second year of life is presented in the main MS 
(Table 2).  
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The association of lung function results between different test occasions for each of the primary 
outcomes is shown in Fig E1. In contrast to the highly significant relationship in both FRCpleth and 
FEV0.5 across all test occasions in infants with CF, LCI at 2yr was not predicted by that measured 
at either 3mth or 1yr. Of note, the majority of ILF results for CF infants remained within the 
normal range at both 1 and 2yrs. Of the 10 CF infants with an abnormal LCI at 1yr, all but two 
had a result within the normal range by ~2yr (Fig 3 and E1). Similarly, only 2/9 infants with 
abnormal LCI at 2yr also had an abnormal 1yr result.  No child had an abnormal LCI on all three 
occasions (Table 3, main manuscript). Similarly, the majority of CF infants with abnormal FRCpleth 
at 2yrs had had normal results at 1yr and vice versa (Fig 3 and E1) with only two children having 
abnormal zFRCpleth on all test occasions. No child with abnormal  zFEV0.5 at ~2yr had had 
abnormal results at either 3mth or 1yr (Fig 3 and E1). 
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Figure E1. Relationship of results between test occasions within each lung function outcome 
in infants and young children with CF (A) and in healthy controls (B).   
A. Cystic Fibrosis    B. Healthy controls 
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A. Cystic Fibrosis    B. Healthy controls 
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A. Cystic Fibrosis    B. Healthy controls 
 
 
 
 
  
 
 
Legend: Relationship of LCI, FRCpleth, and FEV0.5 between various test occasions in children with 
CF and healthy infants. For each outcome, all subjects with results on both test occasions are 
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represented by an individual data point. Limits of normality are shown at 1.96 z-scores for LCI 
and FRCpleth, and -1.96z for FEV0.5. The between-test equivalence line is shown on each cross-
plot as a dashed line. For LCI and FRCpleth, all values to the right of the vertical line or above the 
horizontal cut-off were abnormal. Those in the right upper shaded quadrant were abnormal on 
both occasions (e.g. n=2 subjects with CF for LCI and n=3 with CF for FRCpleth at 2yrs). For FEV0.5, 
values to the left of the vertical line or below the horizontal cut-off were abnormal. The one CF 
infant with abnormal FEV0.5 at both 3 months  and 1 year appears in the shaded left lower 
quadrant. 
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Fig E2. Within-subject variability for infant lung function outcomes in healthy controls, and for 
CF infants according to whether they had ever isolated Pseudomonas aeruginosa, or received 
any IV antibiotics by their 2yr infant lung function test.  
 
LCI 
 
             Control     CF, No PsA CF PsA           Control              CF, No IVAB         CF IVAB
  
 
 
 
FRCpleth 
 
             Control       CF, No PsA   CF PsA                              Control         CF, No IVAB            CF IVAB 
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FEV0.5 
               Control                 CF, No PsA        CF PsA   Control               CF, No IVAB            CF IVAB 
  
 
Legend: Each subject is represented by an individual line. Z-scores for each infant lung function 
(ILF) test (LCI, FRCpleth and FEV0.5) are plotted against actual age at test. Limits of normality are 
represented by the dashed lines at +/- 1.96 z-scores. For infants with cystic fibrosis, plots are 
separated according to Pseudomonas aeruginosa (PsA) status (left hand panel) or whether they 
had ever received intravenous antibiotics (IVAB) (right hand panel) by their 2yr lung function 
test at ~2 years. Infants with CF were considered ‘CF PsA’ if they had ever isolated PsA in culture 
by their 2yr ILF. Control infants are represented on the left of both panels for ease of 
comparison. As can be seen, while there was a tendency for those with an abnormally high LCI 
during the first year of life to improve by 2 years, whereas most infants with abnormal LCI by 2 
years had results within the normal range previously,  no clear pattern was evident.   
  
Page 67 of 72 European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 16 
 
Fig E3. Change in LCI between ~1 and ~2yrs of life plotted against age at final (~2yr) test, 
classified according to Pseudomonas aeruginosa status (A), or treatment with at least one 
course of intravenous antibiotics by final lung function test (B). 
A. Pseudomonas aeruginosa status 
 
B. Intravenous antibiotics 
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Legend: CF infants with LCI measurements at 1 & 2yrs of age are represented with one data 
point per subject. NOTE: In contrast to spirometric outcomes, an increase in zLCI between tests 
is suggestive of deterioration whereas a decrease is suggestive of improvement. Infants with CF 
are classified according to Pseudomonas aeruginosa (PsA) status (A), or treatment with at least 
one course of intravenous (IV) antibiotics by final lung function test (B). In plot A, Infants with 
CF but no isolations of PsA by their ~2year lung function tests are represented by open circles. 
Infants isolating PsA on at least one occasion by their final test are represented by grey filled 
circles. In plot B, infants with CF with no history of ever receiving IV antibiotics by their ~2year 
lung function tests are represented by open circles. Infants with at least one course of IV 
antibiotics by their final test are represented by grey filled circles.  
 
 
 
 
There was no relationship between the magnitude or direction of change in LCI between ~1 and ~2 years 
of life and age at which the final (~2yr) test was performed, nor with either Pseudomonas aeruginosa 
status or history of IV antibiotics by the time of the final ILF visit (Fig E3 and Table E6). While the 
improvement in FEV0.5 during the first year of life was significantly greater in CF infants who did not 
isolate PsA during this period, than in those that did, catch up in the latter group was faster during the 
second year of life (Table E6). 
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Table E6. Comparison of changes (∆) in lung function over time in infants with cystic fibrosis 
(CF) between test dates according to history of Pseudomonas aeruginosa (PsA), (A) or 
intravenous (IV) antibiotics (B) by final (~2year) infant lung function test. 
A) Pseudomonas aeruginosa (ever by 2yr test) 
 3months to 1year 
 CF PsA CF No PsA Difference in change (95% CI) 
∆ zLCI  0.17(1.12), n=29 0.50(1.28), n=25 -0.33(-0.98 to 0.32) 
∆ zFRCpleth 0.07(1.16), n=26 0.00(1.24), n=21 0.07 (-0.63 to 0.78) 
∆ zFEV0.5  0.11(1.07), n=30 0.64(0.76), n=26 -0.53(-1.03 to -0.02)* 
 1 year to 2 years 
 CF PsA CF No PsA Difference in change (95% CI) 
∆ zLCI  0.08(1.56), n=30 -0.09(1.16), n=28 0.17(-0.56 to 0.90) 
∆ zFRCpleth 0.11(1.25), n=30 -0.09(0.98), n=24 0.20(-0.43 to 0.82) 
∆ zFEV0.5  0.38(1.16), n=30 -0.05(0.82), n=24 0.43(-0.13 to 0.99) 
 3months to 2 years 
 CF PsA CF No PsA Difference in change (95% CI) 
∆ zLCI  0.05(1.76), n=29 0.28(1.20), n=27 -0.23(-1.04 to 0.59) 
∆ zFRCpleth 0.34(1.35), n=25 -0.22(1.37), n=22 0.56 (-0.24 to 1.36) 
∆ zFEV0.5  0.43(1.25), n=29 0.51(1.00), n=24 -0.08 (-0.71 to 0.55) 
 
B. IV antibiotics (ever by 2 yr test) 
 3months to 1year 
 CF IVABs CF No IVABs Difference in change (95% CI) 
∆ zLCI  0.48 (1.09), n=23 0.29 (1.30), n=27 0.19 (-0.50 to 0.88) 
∆ zFRCpleth -0.02 (1.20), n=22 0.11 (1.08), n=22 -0.14 (-0.83 to 0.56) 
∆ zFEV0.5  0.22 (1.07), n=25 0.51 (0.90), n=27 -0.29 (-0.84 to 0.27) 
 1 year to 2 years 
 CF IVABs CF No IVABs Difference in change (95% CI) 
∆ zLCI  -0.33 (1.22), n=25 0.2 (1.48), n=30 -0.53 (-1.27 to 0.22) 
∆ zFRCpleth 0.04 (1.28), n=24 -0.03 (1.07), n=27 0.07 (-0.59 to 0.73) 
∆ zFEV0.5  0.41 (1.02), n=24 0.05 (1.07), n=26 0.36 (-0.24 to 0.96) 
 3months to 2 years 
 CF IVABs CF No IVABs Difference in change (95% CI) 
∆ zLCI  -0.10 (1.59), n=24 0.42 (1.51), n=28 -0.52 (-1.39 to 0.34) 
∆ zFRCpleth 0.18 (1.27), n=21 0.01 (1.45), n=22 0.18 (-0.67 to 1.02) 
∆ zFEV0.5  0.58(1.13), n=24 0.43(1.18), n=25 0.16 (-0.51 to 0.82) 
Footnote: Results are presented as the mean (SD) change in z-score for each outcome, between testing 
at approximately   3 months and 1 year, 1 year to 2 years, and 3months to 2 years of age. Numbers (n) 
for each unpaired t-test comparison are shown.  *p<0.05.  
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Sample calculations for randomised control trials (RCTs). 
The results from the current study indicate that, contrary to our previous suggestions [E6, E7], when 
studying a NBS cohort of infants with CF managed according to standard UK protocols, it is not possible 
to identify infants who are at high-risk ‘ for poor lung function by 2 years of age for selective recruitment 
into an RCT. The impact that this would have on power calculations for studies intending to use infant 
LFT as an outcome variable in the first 2 years of life is explained below in two  excerpts from Nguyen et 
al Thorax 2014, which presented results from this cohort at 1yr of age. 
Excerpt from discussion in main MS: Nguyen et al 2014 [E7] 
Using data from this study, results from ∼85 infants/arm would be required to detect relatively small 
differences in lung function (ie, equivalent to 0.5 z-scores) that might occur in response to an 
intervention if unselected NBS CF were recruited to such a trial. By contrast, were recruitment to such a 
RCT limited to a ‘high-risk group’ (ie, abnormal PFTs by 3 months, see online supplementary tables E3 
and E4), a larger treatment effect would be expected, with only 22 infants/arm being required to detect 
a difference of 1 z-score (equivalent to ∼9% for LCI), with 90% power. Such an approach could optimise 
recruitment since parents of infants with early PFT abnormalities would be more likely to consent, and 
also this approach would minimise exposure of children with potentially little to gain from therapy from 
unnecessary side effects. 
 
From Nguyen et al  2014; OLS Section e [E7] 
Sample size calculations depend on numerous factors including the magnitude of change/difference to 
be detected, the number of outcomes under investigation, the between subject variability for any given 
outcome, and the confidence (power) that is desired with which to detect such differences. Taking into 
account the between-subject variability of infant PFTs observed in this and previously published 
studies[E5-7] a difference of 1 z-score (SD) at 1 year equates to ~ 9% or 0.64 units for LCI, 14.5% or 27 
mL for FRCpleth and 15% or 46 mL for FEV0.5. Decisions regarding what constitutes a minimal clinically 
important difference in intervention trials are complex, but values equating to at least 0.5 SD (or z16 
scores) are probably appropriate, to avoid risk of sampling error.[E9] In contrast to studies in older 
children with CF, in whom larger differences in PFTs may be observed,[E10] the mean difference 
between the NBS CF infants and healthy controls at one year for the 3 primary outcomes in this study 
was only 0.5 to 0.8 z-scores (with 95% confidence intervals ranging between 0.2 – 1.2 z-scores, Table 2, 
main manuscript). 
If planning a randomised controlled intervention study with, for example, LCI as a primary endpoint, a 
sample size of 85 subjects per arm would allow detection of differences in lung function at one year of 
age equivalent to 0.5 z-scores at the 5% significance level with 90% power, whereas 63 patients per 
group would provide 80% power to detect the same difference.[E11-13] Given that, despite excellent 
success rates in PFTs and minimal attrition, paired lung function tests at 1 year were ‘only’ attained in 
62% NBS CF infants presenting during the recruitment period (Figure 1), a pool of at least 275 CF infants 
(85 x2 x100/62) would be required to undertake such a study, increasing further if based on more than 
one outcome. However, if recruitment were limited to those with evidence of abnormal lung function at 
3 months, then the magnitude for potential improvement would be considerably larger. Under these 
circumstances, an effective intervention in this ‘high risk group’ could improve lung function by at least 1 
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z-score (Table E4 and E5). Thus a RCT designed to detect a 1 z-score improvement in lung function in 
response to an intervention would only require 22 infants in each arm for 90% power at the 5% 
significance level. Nevertheless, since abnormalities at 3 months were only observed in 30% of our 
infants when based on the 2 most feasible PFTs (LCI and FEV0.5), after allowing for attrition and 
exclusions as discussed above it would still be necessary to access a population of (22 x 2) x (100/62) x 
(100/30) i.e. ~237 NBS CF infants to obtain 90% power in a RCT. This is more than double the number 
identified in the South-East of England over a 2.5 year period during the present study and would hence 
inevitably require a multi-centre study if to be completed in a timely manner. 
References 
 
E1. Cole TJ, Wright CM, Williams AF et al. Designing the new UK-WHO growth charts to enhance 
assessment of growth around birth. Arch Dis Child Fetal Neonatal Ed. 2012;97(3):F219-22. 
E2. Foong RE, Hall GL. Can we finally use spirometry in the clinical management of infants with 
respiratory conditions? Thorax. 2016;71(3):206-7. 
E3. Lum S, Bountziouka V, Wade A, Hoo AF, Kirkby J, Moreno-Galdo A, et al. New reference ranges 
for interpreting forced expiratory manoeuvres in infants and implications for clinical interpretation: a 
multicentre collaboration. Thorax. 2016;71(3):276-83. 
E4. Lum S, Hoo AF, Hulskamp G, Wade A, Stocks J. Potential misinterpretation of infant lung function 
unless prospective healthy controls are studied. Pediatr Pulmonol. 2010;45(9):906-13. 
E5. Brennan LC, Thia LP, Hoo A, Nguyen T, Chudleigh J, Lum S, et al. Evolution of lung function during 
the first two years of life in infants with cystic fibrosis diagnosed by newborn screening (abstract). 
Thorax. 2013;68(Suppl 3):A6-A7. 
E6. Hoo AF, Thia LP, Nguyen TT, Bush A, Chudleigh J, Lum S, et al. Lung function is abnormal in 3-
month-old infants with cystic fibrosis diagnosed by newborn screening. Thorax. 2012;67(10):874-81. 
E7. Nguyen TT, Thia LP, Hoo AF, Bush A, Aurora P, Wade A, et al. Evolution of lung function during 
the first year of life in newborn screened cystic fibrosis infants. Thorax. 2014;69(10):910-7. 
Page 72 of 72European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 21 
 
E8. Thia LP, Hoo AF, Brennan L, Nguyen TT, Chudleigh J, Wade A, et al. Stable lung function is 
maintained over 2 years in newborn screened (NBS) CF infants (abstract). Eur Respir J. 2013;42 Suppl 
57:1072s. 
 
Page 73 of 72 European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
